How short sellers threaten innovations that could benefit patients - Don Seiffert (Boston Business Journal)
No Crying In Biotech: Managing Short Sellers From Strength - David Sable (Forbes)
Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock - Adam Feuerstein (The Street)
Response to Don Seiffert - Matt Barry (Short Selling)
The Promise and Peril of Crispr
John Lauerman and Caroline Chen (Bloomberg BusinessWeek)
25 Years in Biotech
Katrine Bosley
Are Biotech Valuations Sustainable?
Ohad Hammer (ORF blog)
Bring Back Prostate Screening
Deepak Kapoor (New York Times)